CervoMed: HC Wainwright Reiterates Neutral Rating with $11 PT

CervoMed: HC Wainwright Reiterates Neutral Rating with $11 PT

CervoMed Inc. (CRVO), a clinical-stage biotechnology company focused on developing treatments for age-related neurological disorders, has received a neutral rating from H.C. Wainwright & Co. with a price target of $11.00 per share. This rating was announced on September 2, 2025 [1].

The analyst's report highlighted CervoMed's progress in its Phase 2b RewinD-LB trial for neflamapimod, a p38MAPK inhibitor targeting synaptic dysfunction in dementia with Lewy bodies (DLB). The trial demonstrated a 54% risk reduction in clinically significant worsening compared to control, improving to 64% in patients with minimal Alzheimer's disease co-pathology. Additionally, the company reported a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP) at week 32, indicating potential efficacy in slowing neurodegeneration [2].

CervoMed also announced its participation in several upcoming investor conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and Morgan Stanley's 23rd Annual Global Healthcare Conference, both scheduled for September 2025. The company plans to present its latest clinical data and discuss its pipeline of neurological treatments with investors [3].

The company's financial results for the second quarter of 2025 showed grant revenue of $1.8 million, R&D expenses of $5.1 million, and a net loss of $6.3 million. CervoMed reported $33.5 million in cash and equivalents as of June 30, 2025, with funding runway into Q3 2026 [4].

CervoMed's stock price as of September 2, 2025, was $10.095, and its market capitalization was not explicitly stated in the provided materials. However, the company's financial performance and clinical trial results suggest continued investment potential for stakeholders focused on innovative neurological treatments.

References:
[1] https://www.stocktitan.net/news/CRVO/
[2] https://www.stocktitan.net/news/CRVO/
[3] https://www.stocktitan.net/news/CRVO/
[4] https://www.stocktitan.net/news/CRVO/